HTA submission documents

In addition to concise and accurate presentation of supporting scientific data, value for money is a key criteria in drug subsidy or reimbursement decisions. This includes cost effectiveness and added value from comparative effectiveness research (CER). There is increasing requirement for manufacturers to demonstrate the pharmacoeconomic value of their products.


We can help to fill knowledge gaps in the ‘comparative effectiveness’ of products by drafting and synthesizing the evidence required by healthcare decision-makers. This includes indirect comparative effectiveness assessments and pharmacoenocmic research, to well-conducted systematic reviews and meta-analyses.

Transform health

Transform healthcare

Transform education

Transform clinical practice

Transform patient care

Transform manuscripts

Transform info delivery

Transform training

Transform communications

Transform evidence

Transform writing

Transform editing